Another new biotech company to be focused on treatments for CRPC

Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer. … READ MORE …

Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Custirsen shows no benefit in combination with cabazitaxel in mCRPC

Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …

Results we already knew about for cabozantinib in mCRPC

Back in September 2014, Exelixis had announced (and we had reported) the failure of the COMET-1 trial to show a meaningful survival benefit for treatment with cabozantinib in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Personalized medicine is coming to life in management of advanced prostate cancer

A new study reported today in the New England Journal of Medicine is suggesting that every man with metastatic prostate cancer (regardless of his age or family history) should be tested for certain particular inherited mutations. … READ MORE …

Abiraterone + veliparib in treatment of men with mCRPC

Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib.

Ipataserib + abiraterone in the treatment of post-chemo mCRPC

One of the more provocative papers to be presented this year at the annual meeting of  the American Society of Clinical Oncology is by De Bono et al. from a large, randomized Phase II trial of a drug called GDC-0068 or ipataserib. … READ MORE …